天康生物(002100) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,204,813,855.90, representing a 20.92% increase compared to ¥996,366,411.62 in the same period last year[10] - Net profit attributable to shareholders was ¥28,920,108.83, a decrease of 47.66% from ¥55,252,455.82 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥27,206,552.91, down 49.85% from ¥54,249,567.43 in the previous year[10] - Basic earnings per share decreased by 50.00% to ¥0.03 from ¥0.06 in the previous year[10] - Operating profit, total profit, and net profit attributable to the parent company decreased by 89.42%, 89.18%, and 47.66% respectively, mainly due to the impact of swine fever on the food breeding business[25] - Net profit for the current period was ¥24,117.73, a significant decrease from ¥54,354,971.14 in the previous period[60] Cash Flow - The net cash flow from operating activities was ¥97,896,377.87, a significant improvement from a negative cash flow of ¥170,628,029.67 in the same period last year[10] - Cash flow from operating activities increased by 157.37% year-on-year, mainly due to higher revenue and reduced inventory purchases[30] - Cash flow from investing activities decreased by 165.45% year-on-year, primarily due to increased project investments in the current period[30] - Cash flow from financing activities increased by 492.93% year-on-year, reflecting a rise in loans needed for business operations[30] - Cash inflows from operating activities generated a net amount of ¥97,896,377.87, a significant recovery from a negative cash flow of ¥170,628,029.67 in the previous period[70] - Cash inflows from financing activities amounted to ¥699,779,121.20, significantly higher than ¥130,000,000.00 in the previous period, indicating a substantial increase in financing[74] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,486,857,083.03, an increase of 11.50% from ¥8,508,742,207.44 at the end of the previous year[10] - Total current assets increased to ¥5,971,303,638.20 from ¥5,857,658,521.18, reflecting a growth of approximately 1.93%[44] - Non-current assets rose significantly to ¥3,515,553,444.83 from ¥2,651,083,686.26, marking an increase of about 32.6%[44] - Total liabilities increased to ¥5,807,689,083.66 from ¥5,229,930,251.35, representing a rise of about 11.03%[46] - Long-term borrowings surged to ¥1,277,000,000.00 from ¥600,000,000.00, showing a significant increase of 112.83%[46] - The company's total liabilities increased to ¥3,680,982,801.63, compared to ¥3,118,704,637.60 in the previous period, reflecting a growth of 18%[57] Shareholder Information - The net assets attributable to shareholders were ¥3,231,009,815.42, a slight increase of 0.67% from ¥3,209,604,751.62 at the end of the previous year[10] - The top shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 29.47% of the shares, totaling 283,929,184 shares[15] - The company repurchased a total of 6,363,400 shares, accounting for 0.6605% of the total share capital, with a total payment of approximately 29.98 million yuan[31] Expenses - Management expenses increased by 38.18% to 73.30 million yuan due to the addition of new subsidiaries in the reporting period[24] - Financial expenses surged by 326.67% to 42.34 million yuan, primarily due to increased loans from newly added subsidiaries[24] - The company reported a tax expense of ¥4,070,370.58, up from ¥2,870,235.48 in the previous period, reflecting an increase of approximately 42%[66] Inventory and Biological Assets - The company reported a 30.44% decrease in productive biological assets, mainly due to elimination and disease impacts[27] - The company’s inventory rose to ¥206,483,003.81 from ¥188,403,931.81, reflecting an increase of approximately 9.57%[51] Research and Development - Research and development expenses for the current period were ¥12,620,993.58, slightly up from ¥12,587,270.07 in the previous period[58]